PRESS

In the News

Biotricity, News

Biotricity issues shareholder update

Biotricity Inc. (Biotricity) today provided an update for its shareholders by Chief Executive Officer Waqaas Al-Siddiq, Ph.D., that discusses recent company achievements and strategic initiatives to position the business for strong 2022 results, increasing scale and accelerating growth into 2023.


Read More

Biotricity, News

Biotricity to launch commercial sales of its disruptive cardiac monitoring device, Biotres in April 2022

Biotricity Inc. (Biotricity) will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022.  The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since late-February 2022.


Read More

Biotricity, News

Biotricity named to Fast Company’s annual list of the World’s 50 Most Innovative Companies for 2022

Biotricity Inc. (Biotricity) has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2022.  Biotricity was also highlighted as #1 in this year’s Medical Devices category.  This year’s list honors businesses that are making the biggest impact on their industries and culture as a whole-ultimately thriving in today’s ever-changing world.


Read More

My Next Health, News

My Next Health to support NFL funded University of Regina research on concussions and pain management

My Next Health Inc. (MNH) has announced its USD $400,000 in-kind support of the medical research team at the University of Regina in Canada, along with the USD $570,030 awarded from the National Football League (NFL) to investigate the use of cannabinoids, the naturally occurring compounds found in the cannabis plant, in the treatment of concussions and for pain management in football players.


Read More

Green Sky Labs, News

Nurcapital Corporation Ltd. and Green Sky Labs Inc. announce signing of Definitive Agreement and provide update on Proposed Qualifying Transaction

Nurcapital Corporation Ltd. (Nurcapital), a capital pool company, and Green Sky Labs Inc. (GSL) today announced the execution of a definitive business combination agreement (the “Definitive Agreement”) which, subject to certain conditions and applicable TSX Venture Exchange (“TSXV”) approval, will result in the reverse takeover of Nurcapital by GSL and will constitute Nurcapital’s “Qualifying Transaction”, as defined by Policy 2.4 – Capital Pool Companies (“Policy 2.4”) of the TSXV (the “Proposed Qualifying Transaction”).


Read More

1 2 7 8 9
Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from - Youtube
Vimeo
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Spotify
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound